TLR9 and neoplasm: The robust upregulation of IFN-β expression in the tumor and spleen tissue, along with the increased infiltration of CD8+ cells and reduced tumor cell mitosis observed in our study, was mainly due to the synergetic effect of STING and TLR9 agonists when administered in combination forms (Figures 2A, 3A, 4F, 8).